123 related articles for article (PubMed ID: 35244063)
21. Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs.
Mutua V; Henry BM; Csefalvay CV; Cheruiyot I; Vikse J; Lippi G; Bundi B; Mong'are N
Acta Biomed; 2022 Mar; 93(1):e2022014. PubMed ID: 35315395
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.
Rezaei S; Fatemi B; Karimi Majd Z; Minaei H; Peikanpour M; Anjidani N; Taheri A; Dastan F; Mosaed R
Expert Rev Clin Immunol; 2021 May; 17(5):499-511. PubMed ID: 33823733
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
24. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.
Yu SY; Koh DH; Choi M; Ryoo S; Huh K; Yeom JS; Yoon YK
Emerg Microbes Infect; 2022 Dec; 11(1):1154-1165. PubMed ID: 35343397
[TBL] [Abstract][Full Text] [Related]
26. Systemic corticosteroids for the treatment of COVID-19.
Wagner C; Griesel M; Mikolajewska A; Mueller A; Nothacker M; Kley K; Metzendorf MI; Fischer AL; Kopp M; Stegemann M; Skoetz N; Fichtner F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014963. PubMed ID: 34396514
[TBL] [Abstract][Full Text] [Related]
27. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
[TBL] [Abstract][Full Text] [Related]
28. Beneficial and Harmful Effects of Monoclonal Antibodies for the Treatment and Prophylaxis of COVID-19: Systematic Review and Meta-Analysis.
Hernandez AV; Piscoya A; Pasupuleti V; Phan MT; Julakanti S; Khen P; Roman YM; Carranza-Tamayo CO; Escobedo AA; White CM
Am J Med; 2022 Nov; 135(11):1349-1361.e18. PubMed ID: 35878688
[TBL] [Abstract][Full Text] [Related]
29. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
30. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia.
Zhao T; Wu X; Zhang Q; Li C; Worthington HV; Hua F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD008367. PubMed ID: 33368159
[TBL] [Abstract][Full Text] [Related]
31. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
Karampitsakos T; Papaioannou O; Tsiri P; Katsaras M; Katsimpris A; Kalogeropoulos AP; Malakounidou E; Zarkadi E; Tsirikos G; Georgiopoulou V; Sotiropoulou V; Koulousousa E; Chourpiliadi C; Matsioulas A; Lagadinou M; Sampsonas F; Akinosoglou K; Marangos M; Tzouvelekis A
Clin Microbiol Infect; 2023 Mar; 29(3):372-378. PubMed ID: 36273769
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of tocilizumab for COVID-19: a systematic review and meta-analysis of randomized clinical trials.
Almeida PRL; Person OC; Puga MEDS; Giusti MF; Pinto ACPN; Rocha AP; Atallah ÁN
Sao Paulo Med J; 2022; 141(2):168-176. PubMed ID: 36102463
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review.
Rezaei Tolzali MM; Noori M; Shokri P; Rahmani S; Khanzadeh S; Nejadghaderi SA; Fazlollahi A; Sullman MJM; Singh K; Kolahi AA; Arshi S; Safiri S
Rev Med Virol; 2022 Nov; 32(6):e2388. PubMed ID: 36029180
[TBL] [Abstract][Full Text] [Related]
34. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
35. Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic.
Mahroum N; Watad A; Bridgewood C; Mansour M; Nasr A; Hussein A; Khamisy-Farah R; Farah R; Gendelman O; Lidar M; Shoenfeld Y; Amital H; Kong JD; Wu J; Bragazzi NL; McGonagle D
Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501738
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Stroehlein JK; Wallqvist J; Iannizzi C; Mikolajewska A; Metzendorf MI; Benstoem C; Meybohm P; Becker M; Skoetz N; Stegemann M; Piechotta V
Cochrane Database Syst Rev; 2021 May; 5(5):CD015043. PubMed ID: 34029377
[TBL] [Abstract][Full Text] [Related]
37. Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired bacterial and invasive fungal infections.
Minihan B; McAuliffe E; Powell J; Wong SL; Wilkie K; Murphy C; Maher A; Power L; O'Connell NH; Dunne CP
J Hosp Infect; 2022 Aug; 126():29-36. PubMed ID: 35472487
[TBL] [Abstract][Full Text] [Related]
38. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
Rubio-Rivas M; Forero CG; Mora-Luján JM; Montero A; Formiga F; Homs NA; Albà-Albalate J; Sánchez L; Rello J; Corbella X
Pharmacotherapy; 2021 Nov; 41(11):884-906. PubMed ID: 34558742
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of tocilizumab in non-intubated cases with COVID-19: a systematic review and meta-analysis.
Keske Ş; Akyol M; Tanrıöver C; Özlüşen B; Akcan RE; Güler U; Sait B; Kaçmaz B; Gönen M; Ergönül Ö
Infection; 2023 Dec; 51(6):1619-1628. PubMed ID: 37162716
[TBL] [Abstract][Full Text] [Related]
40. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study.
Martínez-Sanz J; Muriel A; Ron R; Herrera S; Pérez-Molina JA; Moreno S; Serrano-Villar S
Clin Microbiol Infect; 2021 Feb; 27(2):238-243. PubMed ID: 32979572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
